Get started
Author

Serigne N. Lo

Observed names: Lo, Serigne N., Serigne N. Lo, Serigne N Lo
ORCID: 0000-0001-5092-5544
Observed ORCID: 0000-0001-5092-5544
OpenAlex ID: A5025668019
Assessment of survival benefit from sentinel node biopsy for melanoma: a systematic review and meta-analysis
2026 · Alexander H R Varey, Marie B Weitemeyer, et al. · The Lancet Oncology · 10
Prospective tumour mutation burden and neoantigen profiling predicts immunotherapy response in metastatic melanoma
2026 · Yizhe Mao, Tuba N. Gide, et al. · npj Precision Oncology · 6
PDF
Timing of Definitive Surgical Management of Primary Cutaneous Melanoma: Association With Survival
2026 · Edward (Ned) Farley, Jake Hindmarch, et al. · ANZ Journal of Surgery · 3
PDF
Molecular Profiling and Matched Targeted Therapy for Patients With Advanced Melanoma: Results From Part 1 of the MatchMEL Study
2026 · Andrea Boutros, Matteo S. Carlino, et al. · JCO Precision Oncology · 2
A randomised pilot trial of perioperative propranolol combined with celecoxib versus standard of care in stage III melanoma: The ProCel study protocol
2026 · Katina J. Selvaraj, Diona L. Damian, et al. · PLoS ONE · 1
PDF
Real-world evaluation of the use of melanoma risk prediction tools by clinicians in Australia: a mixed-methods study
2026 · Gillian Reyes-Marcelino, Rehana A Salam, et al. · British Journal of Dermatology · 1
ASO Visual Abstract: Impact of an Online Risk Calculator for Sentinel Node Positivity on Management of Patients with T1 and T2 Melanomas
2024 · Alec A. Winder, Zoe Boyer, et al. · Annals of Surgical Oncology · 1
PDF
Uptake of sentinel lymph node biopsy following a melanoma diagnosis: an Australian population-based study
2026 · Caroline G. Watts, Janet McKeown, et al. · Surgical Oncology
Staging and prognosis of mucosal melanomas of the head and neck
2026 · Yu Jin Jeong, May Thwin, et al. · Surgical Oncology Insight
PDF
Utility of recurrence-based surrogate endpoints for survival in adjuvant cancer trials: evidence from melanoma
2026 · Sophie E Orme, Serigne N Lo, et al. · JNCI Journal of the National Cancer Institute
Standard neoadjuvant immunotherapy in patients with resectable stage III Melanoma – The early Australian experience
2026 · Francis Proulx-Rocray, Rebecca Symons, et al. · European Journal of Cancer
On the survival benefit from sentinel node biopsy for melanoma – Authors' reply
2026 · Alexander H R Varey, Serigne N Lo, et al. · The Lancet Oncology
Anti–PD-1 (PD-1) monotherapy versus combination with anti–CTLA-4 for metastatic uveal melanoma (MUM) patients (pts).
2026 · Ines Esteves Domingues Pires da Silva, Ronen Stoff, et al. · Journal of Clinical Oncology
PDF
Real world outcomes of neoadjuvant immune checkpoint blockade (ICB) for resectable stage III melanoma: Pathologic response and FDG PET/CT correlates.
2026 · Yang Wang, Aparna Dodla Rao, et al. · Journal of Clinical Oncology
A phase 2 study of neoadjuvant nivolumab (nivo) + relatlimab (rela) in high-risk stage II cutaneous melanoma (NeoReNi).
2026 · Georgina V. Long, Serigne N. Lo, et al. · Journal of Clinical Oncology
PDF
A propensity score-matched analysis comparing first-line regional, systemic, and intralesional treatments for melanoma in-transit metastases in a contemporary patient population.
2026 · Caitlyn Balsay-Patel, Michelle Dugan, et al. · Journal of Clinical Oncology
A phase 3, international, multicenter, randomized, controlled trial of selective index lymph node resection versus therapeutic lymph node dissection after neoadjuvant immunotherapy for stage IIIB-D melanoma (MSLT-3/S2601/EORTC2519).
2026 · Maria Gonzalez, Georgina V. Long, et al. · Journal of Clinical Oncology
NeoIRENIE: A phase 2 randomized trial of intensified neoadjuvant therapy for melanoma patients with multi-omic biomarker or clinically predicted poor response to standard immune checkpoint inhibitor (ICI) therapy.
2026 · Maria Gonzalez, Inês Pires da Silva, et al. · Journal of Clinical Oncology
Seasonal variation in immune-related adverse events in advanced cancer patients
2026 · Roger Liang, Bo Gao, et al. · Cancer Immunology Immunotherapy
Time trends in the incidence of multiple primary melanomas in Australia
2026 · Yuan Ni, David Espinoza, et al. · Cancer Epidemiology
Adaptive trials in low back pain and osteoarthritis: How common are they and when should they be used? A systematic review from ClinicalTrials.gov
2026 · Anelise Moreti Cabral Silveira, Michelle Wang, et al. · Osteoarthritis and Cartilage Open
Prognostic significance of isolated clinically detected regional melanoma metastasis in minor nodal basins
2026 · Mervi Rautalin, Dina Saks, et al. · World Journal of Surgical Oncology
Clinical and pathological characteristics of thin cutaneous melanomas with rapid recurrence
2026 · Prachi Bhave, Terence Wong, et al. · SSRN Electronic Journal
Effectiveness of a stepped-care model to address fear of cancer recurrence in patients with early-stage melanoma: results at 6- and 12-month follow-up
2025 · Jake R. Thompson, Lisa Gomes, et al. · Supportive Care in Cancer
From significance to relevance: raising the bar for harm in dermatology
2025 · Joerg Albrecht, Jo Leonardi-Bee, et al. · British Journal of Dermatology
PDF
Works count: 26
Citation count: 24
H-index: 3
I10-index: 1
Year
Topic
Type